On June 19, Yichang Pharmacy (600566.SH) announced that its wholly-owned subsidiary Yichang Pharmacy Group Co., Ltd. (referred to as "Yichang Limited") has received the "Drug Registration Certificate" for desloratadine hydrochloride dry suspension approved and issued by the National Drug Administration. Desloratadine hydrochloride is a second-generation H1 receptor antagonist that selectively blocks H1 receptors. It is the main active metabolite of terfenadine and has anti-histamine activity.
济川药业(600566.SH)：盐酸非索非那定干混悬剂获得药品注册证书
Jichuan Pharmaceutical (600566.SH): Fexofenadine hydrochloride dry suspension obtained drug registration certificate
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.